Breaking News & Company Info
Get access to Genentech information and resources for stories in development. Find recent and archived press releases.
On average, 5-20% of the US population gets the flu each year, and more than 200,000 are hospitalized from seasonal flu related complications. To recognize flu symptoms, remember Flu F.A.C.T.S. (Fever, Aches, Chills, (extreme) Tiredness, and Sudden Onset).
On November 14, 2014, a Genentech medicine received FDA approval for the treatment of women with platinum-resistant, recurrent, epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received no more than two prior chemotherapy regimens.
On October 15, 2014, the FDA approved a medicine for the treatment of idiopathic pulmonary fibrosis (IPF).
On August 14, 2014, a Genentech medicine received FDA approval for use in persistent, recurrent or metastatic cervical cancer. It is the first biologic medicine approved in combination with chemotherapy to help women with this type of cancer live longer than with chemotherapy alone.
On July 1, 2014, Genentech entered into an agreement to acquire Seragon Pharmaceuticals, Inc., a privately held biotechnology company based in San Diego, California.
FDA Approves Xolair® (omalizumab) for Subcutaneous Use for People with Chronic Idiopathic Urticaria (CIU), a Form of Chronic Hives
On March 21, 2014, the FDA approved a Genentech medicine for people 12 years of age and older for the treatment of chronic idiopathic urticaria (CIU), a form of chronic hives.
On November 1, 2013, the FDA approved a new Genentech medicine for people with previously untreated CLL. It was the first medicine approved with the FDA’s Breakthrough Therapy Designation.
Genentech to report new advances at the American Society of Clinical Oncology Annual MeetingGenentech will present important new data from studies of several cancer medicines at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO) from May 31-June 4, 2013, in Chicago.This page is intended to be a media resource for Genentech developments at ASCO. It will be updated frequently throughout the meeting.
FDA Approves First Personalized Medicine for EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer in the United States
On May 14, 2013, the FDA approved a personalized medicine for people newly diagnosed with a genetically distinct type of metastatic NSCLC.
Genentech built an iPad app that turns a primary genetic concept into a maddeningly addictive mobile game.
On February 22nd, 2013, the FDA approved a new personalized Genentech medicine for people with an aggressive form of breast cancer.
FDA Approves New Use of Avastin Plus Fluoropyrimidine-Based Chemotherapy in Metastatic Colorectal Cancer
On January 23, 2013, a Genentech medicine received FDA approval for a new use in metastatic colorectal cancer.
On October 12, 2012, a Genentech medicine received approval from the FDA to expand its indication for Rheumatoid Arthritis.
gRide, Genentech's employee commuting program, has saved 100 million miles of driving since the program's inception began in late 2006. The program began as a way to reduce the number of vehicles that travel to and park on the South San Francisco campus.
On August 10, 2012, a Genentech medicine was approved by the FDA for diabetic macular edema (DME).
On June 8, 2012, a Genentech medicine was approved by the FDA for previously untreated HER2-positive metastatic breast cancer.
Genentech, the Banner Alzheimer's Institute, and the National Institutes of Health are collaborating on the first-ever prevention trial in cognitively healthy individuals who are likely to develop Alzheimer's disease due to their genetic history.
On January 30, 2012, a Genentech medicine was approved by the FDA for the treatment of adults with a type of skin cancer, called basal cell carcinoma (BCC), that has spread to other parts of the body or that has come back after surgery or that their healthcare provider decides cannot be treated with surgery or radiation.
On August 17, 2011, a Genentech medicine was approved by the FDA for a type of inoperable or metastatic melanoma.
Genentech Goes to Town takes place September 13 to September 24 in South San Francisco, Vacaville, Oceanside and Hillsboro. The Genentech Goes to Town program supports our communities by providing employees with special "GenenMoney" to spend at local businesses.